CDH22

Across TCGA pan-cancer cohorts, CDH22 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CDH22 data layer compared with 8 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CDH22 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated CDH22 expression acts as an unfavorable survival marker, although some lineages such as KICH and KIRP show a favorable association.

OV, KICH, and KIRP are the cancer types where CDH22 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Quartile	III,IV	0.606	0.744	.003	74	view →
KICH	OS	Median	II,III,IV	0.964	0.626	.002	46	view →
KIRP	DFS	Median	All	1.000	0.790	.002	38	view →
LGG	DFS	Median	All	0.466	0.341	<.001	38	view →
BRCA	OS	Median	All	0.635	0.511	.001	37	view →
ACC	DFS	Tertile	III,IV	0.756	0.160	.002	35	view →
UCEC	DFS	Median	All	0.860	0.931	.001	34	view →
UCS	DFS	Median	II,III,IV	0.603	0.273	.006	30	view →
LUAD	DFS	Tertile	IV	0.334	0.829	.010	18	view →
KIRC	OS	Median	All	0.572	0.688	.004	17	view →
SCLC	OS	Median	II,III,IV	0.718	0.392	.002	16	view →
SKCM	DFS	Median	IV	0.726	0.168	<.001	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CDH22–OV (OS)

Open the OV breakdown →